A5067477750- Birth, Development, and Health
- Dialysis and Renal Disease Management
- Metabolism and Genetic Disorders
- Growth Hormone and Insulin-like Growth Factors
- Renal Diseases and Glomerulopathies
- Childhood Cancer Survivors' Quality of Life
- Parathyroid Disorders and Treatments
- Adolescent and Pediatric Healthcare
- Chronic Kidney Disease and Diabetes
- Pediatric Urology and Nephrology Studies
- Renal function and acid-base balance
- Sexual Differentiation and Disorders
- Systemic Lupus Erythematosus Research
- Blood Pressure and Hypertension Studies
- Electrolyte and hormonal disorders
- Renal Transplantation Outcomes and Treatments
- Transplantation: Methods and Outcomes
- Neonatal Health and Biochemistry
- Autoimmune Bullous Skin Diseases
- Pancreatitis Pathology and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Magnesium in Health and Disease
- Protein Tyrosine Phosphatases
- Child Nutrition and Feeding Issues
- Fibroblast Growth Factor Research
University of California, Los Angeles
1993-2024
Mattel Children's Hospital
2006-2024
UCLA Health
2021
Pediatrics and Genetics
2011
Boston Children's Hospital
2001-2003
Cedars-Sinai Medical Center
1998
Oklahoma State University Center for Health Sciences
1991-1997
Stony Brook University
1992
State University of New York
1992
UCLA Medical Center
1991
The relationship between parathyroid hormone, fibroblast growth factor 23 (FGF-23), and indices of bone turnover mineralization in children with early CKD is unknown; thus, this study characterizes the features renal osteodystrophy their to biochemical markers mineral metabolism.
Article Five Years Experience with Recombinant Human Growth Hormone Treatment of Children Chronic Renal Failure was published on January 1, 1994 in the journal Journal Pediatric Endocrinology and Metabolism (volume 7, issue 1).
Background and objectives There is renewed interest in adrenocorticotropic hormone (ACTH) for the treatment of nephrotic syndrome. We evaluated efficacy safety ACTH children with frequently relapsing or steroid-dependent syndrome a randomized trial. Design, setting, participants, & measurements Participants aged 2–20 years old were enrolled from 16 sites United States 1:1 to (repository corticotropin injection) no relapse-preventing treatment. regimen was 80 U/1.73 m 2 administered twice...
Recombinant human growth hormone (rhGH) was administered to 13 pediatric renal allograft recipients, ages 7.6 17.7 yr, who were 14 92 months posttransplant and retarded as manifested by either a standard deviation (SD) more negative than -2.00 or height velocity index of less 25%. The rhGH given daily thrice weekly (0.375 mg/kg/wk) for period 12 36 months. Growth increased from 2.7 +/- 2.1 SD the 12-month before initiation treatment 6.3 2.9 (P 0.00005) 5.2 0.02) after 24 treatment,...
We studied a 14 year-old boy with partial DiGeorge syndrome (DGS), status post complete repair of Tetralogy Fallot, who developed antiphospholipid (APS) and type III mixed cryoglobulinemia. He presented recurrent fever dyspnea upon exertion secondary to right pulmonary embolus on chest computed tomography (CT). Coagulation studies revealed homozygous methylene tetrahydrofolate reductase 677TT mutations, elevated cardiolipin IgM antibodies, beta(2)-glycoprotein I antibodies. Infectious...
Angiotensin II type 1 receptor activating autoantibodies (AT1R-AAs) have gained attention in solid organ transplant as non-HLA antibodies associated with rejection, vasculopathy, and graft dysfunction. These also been reported the context of pre-eclampsia, scleroderma, isolated hypertension. Here, we present 3 post-hematopoietic stem cell (HSCT) cases patients demonstrating elevated levels AT1R-AAs detected within first year post-HSCT. All had hypertension, 2 exhibited profound diarrhea...